- Home
- FCO vs ADAG Comparison
FCO vs ADAG Comparison
Compare FCO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- ADAG
- Stock Information
- Founded
- FCO 1991
- ADAG 2011
- Country
- FCO United Kingdom
- ADAG China
- Employees
- FCO N/A
- ADAG N/A
- Industry
- FCO Investment Managers
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- ADAG Health Care
- Exchange
- FCO Nasdaq
- ADAG Nasdaq
- Market Cap
- FCO 81.4M
- ADAG 95.6M
- IPO Year
- FCO N/A
- ADAG 2021
- Fundamental
- Price
- FCO $5.97
- ADAG $2.14
- Analyst Decision
- FCO
- ADAG Strong Buy
- Analyst Count
- FCO 0
- ADAG 1
- Target Price
- FCO N/A
- ADAG $5.00
- AVG Volume (30 Days)
- FCO 100.1K
- ADAG 73.9K
- Earning Date
- FCO 01-01-0001
- ADAG 07-25-2024
- Dividend Yield
- FCO 14.96%
- ADAG N/A
- EPS Growth
- FCO N/A
- ADAG N/A
- EPS
- FCO 0.43
- ADAG N/A
- Revenue
- FCO N/A
- ADAG $815,746.00
- Revenue This Year
- FCO N/A
- ADAG N/A
- Revenue Next Year
- FCO N/A
- ADAG $2.70
- P/E Ratio
- FCO $12.30
- ADAG N/A
- Revenue Growth
- FCO N/A
- ADAG N/A
- 52 Week Low
- FCO $4.73
- ADAG $1.34
- 52 Week High
- FCO $6.63
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- FCO 48.57
- ADAG 37.47
- Support Level
- FCO $5.96
- ADAG $2.20
- Resistance Level
- FCO $6.16
- ADAG $3.14
- Average True Range (ATR)
- FCO 0.10
- ADAG 0.30
- MACD
- FCO -0.00
- ADAG -0.09
- Stochastic Oscillator
- FCO 43.18
- ADAG 18.63
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets, and Sub-Investment Grade Developing Markets.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.